Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis

Table 1 Number of studies, patients and their distributions included in each analysis by the immunohistochemistry technique

IHC ANALYSIS	Studies	Patients	TP	FP	FN	TN
CK-19[10, 14–33]	21	3603	1697 (47.1%)	433 (12.0%)	314 (8.7%)	1159 (32.2%)
GAL-3[10, 14–17, 19, 21, 25–56]	39	5168	2270 (43.9%)	528 (10.2%)	408 (7.9%)	1962 (38.0%)
HBME-1[10, 14–19, 21, 24–27, 29, 30, 41, 51, 57–61]	21	3900	1501 (38.5%)	324 (8.3%)	436 (11.2%)	1639 (42.0%)
CK-19 + HBME-1[14, 17]	2	157	84 (53.5%)	2 (1.3%)	14 (8.9%)	57 (36.3%)
GAL-3 + CK-19[14, 17]	2	164	90 (54.9%)	6 (3.7%)	9 (5.5%)	59 (36.0%)
GAL-3 + HBME-1[14, 17, 46, 51]	4	293	119 (40.6%)	15 (5.1%)	40 (13.7%)	119 (40.6%)
GAL-3 + HBME-1 + CK-19[14, 17, 29]	3	231	121 (52.4%)	3 (1.3%)	22 (9.5%)	85 (36.8%)

LEGEND: TP (true-positive), FP (false-positive), FN (false-negative) and TN (true-negative).

ISSN: 1746-1596